Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies

Adv Ther. 2022 Oct;39(10):4772-4778. doi: 10.1007/s12325-022-02257-4. Epub 2022 Aug 16.

Abstract

Real-world evidence (RWE) is increasingly used to complement clinical trial data for regulatory decision-making and in certain cases utilized to establish the clinical effectiveness of a therapy. However, the use of RWE is not applicable for all regulatory submissions, and it can be challenging to identify appropriate use cases. An interactive tool was developed ("Decision Aid," https://sn.pub/TpDjZx ) to assist researchers, industry, and other stakeholders in identifying regulatory situations that can benefit from leveraging RWE by organizing precedent cases based on a given regulatory objective (new product approval, labeling expansion for new indication or additional clinical data, post-marketing requirement) and type of RWE study design (external control, observational study, pragmatic trial). Key success factors ensuring fit-for-purpose data and rigorous methods (e.g., clear endpoints, minimizing bias, data completeness) are also described. The tool allows the user to navigate through the precedent cases by selecting certain regulatory objectives and/or study designs. The Decision Aid supports regulatory activities in the RWE space and encourages further use of RWE in regulatory decision-making.

Keywords: Decision Aid; External control; Observational study; Pragmatic trial; Real-world evidence; Regulatory decision-making.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Decision Making*
  • Decision Support Techniques
  • Humans
  • Research Design*
  • Treatment Outcome